Quick Takeaways
- TANG CAPITAL MANAGEMENT LLC filed SCHEDULE 13G/A for Spyre Therapeutics, Inc. Common Stock, par value $0.0001 per share (SYRE).
- Disclosed ownership: 2.4%.
- Date of event: 31 Dec 2025.
Quoteable Key Fact
"TANG CAPITAL MANAGEMENT LLC disclosed 2.4% ownership in Spyre Therapeutics, Inc. Common Stock, par value $0.0001 per share (SYRE) on 31 Dec 2025."
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
See Original Filing| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| TANG CAPITAL MANAGEMENT, LLC | 2.4% | 1,892,200 | 0 | 1,892,200 | /s/ Kevin Tang | Manager | |
| KEVIN TANG | 2.4% | 1,892,200 | 0 | 1,892,200 | /s/ Kevin Tang | Self | |
| TANG CAPITAL PARTNERS, LP | 1.3% | 1,012,338 | 0 | 1,012,338 | /s/ Kevin Tang | Manager, Tang Capital Management, LLC, General Partner | |
| TANG CAPITAL PARTNERS INTERNATIONAL, LP | 1.1% | 879,862 | 0 | 879,862 | /s/ Kevin Tang | Manager, Tang Capital Management, LLC, General Partner | |
| TANG CAPITAL PARTNERS III, INC | 0% | 0 | 0 | 0 | /s/ Kevin Tang | Chief Executive Officer | |
| TANG CAPITAL PARTNERS IV, INC | 0% | 0 | 0 | 0 | /s/ Kevin Tang | Chief Executive Officer |